Following an abandoned collaboration agreement between a complex peptide formulator and a generic manufacturer, CRA was retained to support an academic senior consultant in the ensuing arbitration. CRA’s team examined lost profit damages for the formulator, examining uptake and pricing of the specialty drug with an orphan drug indication. The matter ultimately settled.
Looking ahead to 2026: Trends and expectations for International Arbitration
Across both investor-state and commercial cases, quantum debates have recently turned on attribution under concurrent shocks, the interaction of contract terms...